Active, not recruitingPHASE1, PHASE2NCT00392353
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
Studying Acquired idiopathic sideroblastic anemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Lewis R Silverman, MDMontefiore Medical Center - Moses Campus
- Intervention
- Azacitidine(drug)
- Enrollment
- 135 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2006 – 2026
Study locations (7)
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
- North Shore University Hospital, Manhasset, New York, United States
- Mount Sinai Hospital, New York, New York, United States
- NYP/Weill Cornell Medical Center, New York, New York, United States
- Montefiore Medical Center-Weiler Hospital, The Bronx, New York, United States
- Montefiore Medical Center - Moses Campus, The Bronx, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00392353 on ClinicalTrials.govOther trials for Acquired idiopathic sideroblastic anemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06270771OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot StudySunnybrook Health Sciences Centre
- RECRUITINGNANCT04869683Biocollection in MyeloDysplastic Syndrome (P-MDS)University Hospital, Brest
See all trials for Acquired idiopathic sideroblastic anemia →